ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

In vitro susceptibility of Candida spp to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution MIC methods

In vitro susceptibility of Candida spp to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution MIC methods
Species Antifungal agents Number of
isolates tested		 MIC, mcg/mL
Range 50 percent* 90 percent*
Candida albicans Amphotericin B 2728 0.016 to 4 0.5 0.5
Flucytosine 5208 0.12 to 128 0.25 1
Fluconazole 5827 0.12 to 128 0.25 0.5
Isavuconazole 1056 0.008 to 0.03 0.008 0.008
Itraconazole 3895 0.03 to 8 0.06 0.12
Posaconazole 5827 0.007 to 2 0.015 0.06
Voriconazole 5826 0.007 to 4 0.007 0.015
Anidulafungin 2869 0.007 to 2 0.03 0.06
Caspofungin 2869 0.007 to 0.5 0.03 0.06
Micafungin 2869 0.007 to 1 0.015 0.03
C. glabrata Amphotericin B 949 0.03 to 16 2 4
Flucytosine 1267 0.12 to 128 0.12 0.12
Fluconazole 1517 0.25 to 128 8 32
Isavuconazole 489 0.008 to 8 0.06 1
Itraconazole 1054 0.03 to 8 1 2
Posaconazole 1517 0.03 to >8 1 2
Voriconazole 1516 0.007 to 8 0.25 1
Anidulafungin 747 0.015 to 4 0.06 0.12
Caspofungin 747 0.015 to >8 0.03 0.06
Micafungin 747 0.007 to 1 0.015 0.015
C. parapsilosis Amphotericin B 666 0.25 to 16 1 2
Flucytosine 1047 0.12 to 128 0.12 0.25
Fluconazole 1542 0.12 to 128 0.5 2
Isavuconazole 349 0.008 to 0.5 0.008 0.03
Itraconazole 1028 0.03 to 2 0.25 0.5
Posaconazole 1542 0.007 to 1 0.06 0.12
Voriconazole 1541 0.007 to 8 0.015 0.06
Anidulafungin 759 0.03 to 4 2 2
Caspofungin 759 0.015 to 4 0.25 1
Micafungin 759 0.015 to 2 1 1
C. tropicalis Amphotericin B 528 0.06 to 32 1 2
Flucytosine 759 0.12 to 128 0.25 1
Fluconazole 1198 0.12 to 128 0.5 2
Isavuconazole 187 0.008 to 2 0.008 0.03
Itraconazole 839 0.03 to 8 0.12 0.25
Posaconazole 1198 0.015 to 2 0.06 0.12
Voriconazole 1197 0.007 to 8 0.03 0.06
Anidulafungin 625 0.007 to 2 0.03 0.06
Caspofungin 625 0.007 to >8 0.03 0.06
Micafungin 625 0.007 to 1 0.03 0.06
C. krusei Amphotericin B 143 0.03 to 16 4 8
Flucytosine 184 0.12 to 128 16 32
Fluconazole 305 8 to 128 32 64
Isavuconazole 68 0.06 to 1 0.25 0.5
Itraconazole 206 0.06 to 4 0.5 1
Posaconazole 305 0.03 to 4 0.25 1
Voriconazole 305 0.06 to 4 0.25 0.5
Anidulafungin 136 0.015 to 0.5 0.06 0.06
Caspofungin 136 0.015 to 1 0.12 0.25
Micafungin 136 0.015 to 0.25 0.06 0.12
C. guilliermondii Amphotericin B 102 0.06 to 32 0.25 1
Flucytosine 100 0.12 to 4 0.12 0.5
Fluconazole 138 0.5 to 32 4 8
Isavuconazole 13 0.03 to 4 0.5 4
Itraconazole 90 0.06 to 4 0.5 1
Posaconazole 138 0.015 to 2 0.25 0.5
Voriconazole 138 0.015 to 2 0.06 0.12
Anidulafungin 61 0.12 to 4 1 2
Caspofungin 61 0.03 to >8 0.5 1
Micafungin 61 0.015 to 2 0.5 1
C. lusitaniae Amphotericin B 103 0.06 to 16 0.25 1
Flucytosine 82 0.12 to 128 0.12 0.5
Fluconazole 133 0.12 to 64 0.5 1
Isavuconazole 51 0.008 to 0.5 0.008 0.03
Itraconazole 89 0.03 to 1 0.12 0.25
Posaconazole 133 0.015 to 1 0.03 0.12
Voriconazole 133 0.007 to 1 0.007 0.015
Anidulafungin 58 0.06 to 1 0.5 0.5
Caspofungin 58 0.03 to 1 0.25 0.5
Micafungin 58 0.03 to 1 0.12 0.25
CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.
* MIC encompassing 50 percent and 90 percent of isolates tested, respectively.
¶ Amphotericin B MICs determined by Etest.
Data from:
  1. Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.
  2. Pfaller, MA, Messer, SA, Boyken, L, et al. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518.
  3. Pfaller, MA, Messer, SA, Boyken, L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004; 42:3137.
  4. Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005; 43: 3807.
  5. Pfaller, MA, Messer, SA, Boyken, L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551.
  6. Castanheira M, Messer SA, Rhomberg PR, et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: Application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 2014; 178: 1.
  7. Pfaller MA, Rhomberg PR, Wiederhold NP, et al. In vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories. Antimicrob Agents Chemother 2018; 62:e01230.
Graphic 51523 Version 7.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟